Cryo-Cell International, Inc. CCEL

Competitive advantage analysis · healthcare

Corporate Default
Overall moat score
40/100
Developing

Ranked against 57 peers in Medical Care Facilities

About Cryo-Cell International, Inc.

Cryo-Cell International, Inc. engages in cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells, which are used in regenerative medicine to treat a range of conditions. … Full CCEL analysis →

Key strengths

  • Revenue Growth Consistent Revenue growth volatility is low (stability score 0.75), suggesting sticky customer base.
  • Cash Generation Consistent Cash generation is consistent (score 0.96), indicating reliable business model.

Key risks

  • ROIC Below WACC or Peers ROIC at 32.1th percentile suggests inefficient capital deployment.
  • Elevated Debt Risk Debt serviceability is weak (score 0.24), raising refinancing risk.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Developing
32
Premium

Signals, strengths and risks for Pricing Power

Premium

Signals, strengths and risks for Cost Advantage

Premium

Signals, strengths and risks for Customer Stickiness

Premium

Signals, strengths and risks for Capital Efficiency

Premium

Signals, strengths and risks for Resilience

Premium

Signals, strengths and risks for Scale & Market Position

Where CCEL ranks in Medical Care Facilities

Cryo-Cell International, Inc. ranks #33 of 58 scored companies in Medical Care Facilities by moat score — the top 57%. The widest moat in the group is Encompass Health Corporation (EHC) at 77/100.

# Company Moat score Rating
29 LifeStance Health Group, Inc. LFST 48/100 Developing
30 InnovAge Holding Corp. INNV 44/100 Developing
31 Enhabit, Inc. EHAB 43/100 Developing
32 Astrana Health Inc. ASTH 40/100 Developing
33 Cryo-Cell International, Inc. CCEL 40/100 Developing
34 Brookdale Senior Living Inc. BKD 40/100 Developing
35 The Joint Corp. JYNT 38/100 Developing
36 Sonida Senior Living, Inc. SNDA 37/100 Developing
37 American Oncology Network, Inc. AONC 36/100 Developing

See every General Corporate company ranked by moat score →

How CCEL scores on the Corporate Default defenses

Pricing Power

Score 32 · 20% of the moat score

Pricing power is the ability to raise prices without losing volume.

Cost Advantage

Score 28 · 15% of the moat score

A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.

Customer Stickiness

Score 88 · 15% of the moat score

Stickiness is what makes revenue repeat without being re-won every year.

Capital Efficiency

Score 21 · 18% of the moat score

Capital efficiency asks what the company earns on the money tied up in the business.

Resilience

Score 35 · 17% of the moat score

Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.

Scale & Market Position

Score 46 · 15% of the moat score

Scale matters only when it converts into economics.

How each Corporate Default defense is measured, in full →

Understanding CCEL's moat

What is Cryo-Cell International, Inc.'s moat score?

Cryo-Cell International, Inc. (CCEL) scores 40 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as developing. It ranks #33 of 58 scored companies in Medical Care Facilities, the top 57%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 57 companies in Medical Care Facilities. Its strongest defense is Customer Stickiness (88/100) and its weakest is Capital Efficiency (21/100).

How does Cryo-Cell International, Inc. compare with other Medical Care Facilities companies?

Cryo-Cell International, Inc. ranks #33 of 58 scored companies in Medical Care Facilities by moat score. The widest moat in Medical Care Facilities is Encompass Health Corporation (EHC) at 77/100. The companies ranked closest are Astrana Health Inc. (ASTH) at 40 just above it and Brookdale Senior Living Inc. (BKD) at 40 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 57 companies in Medical Care Facilities. The defenses are then weighted to produce the overall score out of 100.

Why is Cryo-Cell International, Inc. scored with the Corporate Default template?

Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.

Which competitive defenses are measured for Cryo-Cell International, Inc.?

The Corporate Default template measures 6 defenses, and CCEL scores: Pricing Power (32), Cost Advantage (28), Customer Stickiness (88), Capital Efficiency (21), Resilience (35), Scale & Market Position (46). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000